Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Connect Biopharma Holdings Ltd ADR (CNTB)

Connect Biopharma Holdings Ltd ADR (CNTB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,449
  • Shares Outstanding, K 55,072
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,500 K
  • 60-Month Beta -0.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.74
Trade CNTB with:

Options Overview Details

View History
  • Implied Volatility 486.30% ( +210.18%)
  • Historical Volatility 151.13%
  • IV Percentile 86%
  • IV Rank 36.23%
  • IV High 1,145.92% on 08/16/23
  • IV Low 111.51% on 10/27/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 50
  • Open Int (30-Day) 76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +13.33%
on 03/26/24
2.6600 -48.87%
on 04/02/24
+0.0900 (+7.09%)
since 03/25/24
3-Month
0.9000 +51.11%
on 02/01/24
2.6600 -48.87%
on 04/02/24
+0.0600 (+4.62%)
since 01/25/24
52-Week
0.5347 +154.35%
on 09/21/23
2.8400 -52.11%
on 11/17/23
+0.3290 (+31.91%)
since 04/25/23

Most Recent Stories

More News
Stocks Set To Open Lower As Investors Await Fed Meeting, Banking Sector Remains In Focus

June S&P 500 futures (ESM23) are down -0.13%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.10% this morning after three major U.S. benchmark indices closed in the red on Friday as ongoing concerns...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
MARA : 19.01 (-0.42%)
HUT : 8.86 (-1.34%)
RIOT : 12.11 (+1.94%)
UBS : 27.49 (+0.48%)
CS : 0.8858 (+0.99%)
FRC : 3.51 (-43.30%)
CNTB : 1.3600 (-0.73%)
PLD : 103.35 (+0.16%)
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases,...

CNTB : 1.3600 (-0.73%)
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases,...

CNTB : 1.3600 (-0.73%)
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases,...

CNTB : 1.3600 (-0.73%)
SVB Securities Thinks Connect Biopharma Holdings’ Stock is Going to Recover

SVB Securities analyst Thomas Smith reiterated a Buy rating on Connect Biopharma Holdings (CNTB – Research Report) on July 12. The company's shares closed last Wednesday at $0.92, close to its 52-week...

CNTB : 1.3600 (-0.73%)
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in China Remains...

CNTB : 1.3600 (-0.73%)
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the...

CNTB : 1.3600 (-0.73%)
All You Need to Know About Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Rating Upgrade to Buy

Connect Biopharma Holdings Limited Sponsored ADR (CNTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CNTB : 1.3600 (-0.73%)
Connect Biopharma to Participate at the Jefferies Healthcare Conference

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the...

CNTB : 1.3600 (-0.73%)
Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the...

CNTB : 1.3600 (-0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. The company's product candidate includes CBP-201. Connect...

See More

Key Turning Points

3rd Resistance Point 1.4933
2nd Resistance Point 1.4467
1st Resistance Point 1.4033
Last Price 1.3600
1st Support Level 1.3133
2nd Support Level 1.2667
3rd Support Level 1.2233

See More

52-Week High 2.8400
Fibonacci 61.8% 1.9594
Fibonacci 50% 1.6873
Fibonacci 38.2% 1.4153
Last Price 1.3600
52-Week Low 0.5347

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar